Group calls for concise, user-friendly drug info

Share this article:

Prescription drug information for patients should be confined to a single, concise document, according to a National Consumers League (NCL) petition filed with the FDA.

“Patients [filling prescriptions] do not need to receive multiple and lengthy pieces of paper that are often redundant and may even contain conflicting information,” said Sally Greenberg, executive director of the NCL, in a statement.

The petition, signed by several national healthcare organizations such as the National Association of Chain Drug Stores, the National Community Pharmacists Association, the National Alliance for Caregivers, and others, suggests that an “FDA-approved, concise, plain language, single patient document” could supplant the myriad patient package inserts, pharmacy medication guides, consumer medication information documents and full professional labeling.

The current information supplied to patients by pharmacies is the result of several FDA legal requirements, or varied, informal interpretations of said requirements, according to the NCL. Some of the regulations are antiquated, or weren't intended for consumers.

“It is important that patients receive clear, useful information in plain language with their prescription drugs,” said Greenberg in the statement. “They should be able to talk to their pharmacist about potential interactions, how to take their medicine and what side effects to expect."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...